| Symbol | BGLC |
|---|---|
| Name | BIONEXUS GENE LAB CORP |
| Sector | HEALTH CARE |
| Region | Asia |
| Industry | Medical Specialities |
| Address | NO. 8 JALAN KERINCHI,THE VERTICAL BUSINESS SUITE II, UNIT 02, LEVEL 10, TOWER B, KUALA LUMPUR, 59200, Malaysia |
| Telephone | +60 122126512 |
| Fax | — |
| — | |
| Website | https://www.bionexusgenelab.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001737523 |
| Description | BioNexus Gene Lab Corp is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It focuses on developing and marketing safe, effective, and non-invasive blood tests for the early detection of diseases. The companys non-invasive blood tests analyze changes in ribonucleic acid (or RNA) to detect the potentiality of 11 different diseases. These diseases include eight cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon), two bowel diseases (colitis and Crohn), and osteoarthritis. Additional info from NASDAQ: |
BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit
Read more(99% Neutral) BIONEXUS GENE LAB CORP (BGLC) Announces Business Combination
Read moreBioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
Read moreNew Form 10-K - BioNexus Gene Lab Corp <b>Filed:</b> 2026-04-14 <b>AccNo:</b> 0001477932-26-002218 <b>Size:</b> 8 MB
Read moreNew Form NT 10-K - BioNexus Gene Lab Corp <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0001477932-26-001877 <b>Size:</b> 21 KB
Read moreBioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
Read moreBioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
Read more(10% Negative) BioNexus Gene Lab Corp (BGLC) Announces Delay in commence Development Timeline Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Efficacy Assessment
Read more